Navigation Links
Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/10/2008

- Presentation to be Webcast -

MONTVALE, N.J. ,Nov. 10 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) announced today that Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista will present at the upcoming 10th Annual Investor Forum on Tuesday, November 11, at 2:25 p.m. Eastern Time. The event will be held November 10th - 12th at the New York Palace Hotel in New York City.

Dr. Berkowitz will discuss the company's planned commercialization of its haptoglobin test kit for diabetes and ongoing Phase 2 initiatives for alagebrium in heart failure. He will also provide an update of recent milestones.

The presentation will be simultaneously webcast and can be viewed live on the investor relations section of the Company's website at http://www.synvista.com. Participants are encouraged to log on to the webcast approximately five to ten minutes prior to the start of the presentation. It will be archived there after the event.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing diagnostics and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a clinical diagnostic test for Hp2-2 Diabetes, a disease affecting almost 7 million patients in the United States. The genetic or protein form of this test can be used to identify diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of Vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral ant
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
2. Synvista Therapeutics Posts Letter to Stockholders on Web Site
3. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
4. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
5. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
7. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
8. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
9. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
10. Synvista Therapeutics to be Featured on Wallst.net
11. Synvista Therapeutics to Present at the BIO InvestorForum 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Clintrax ... services located in Raleigh, NC ... Evans as Vice President of Administration. ... will oversee all corporate processes, including their alignment ... Clintrax Global, Brad worked as an HR executive, ...
(Date:8/20/2014)... 2014 High performance computing (HPC) ... most complete climate and Earth system model to ... issues. , Eight national laboratories, including Lawrence ... Center for Atmospheric Research, four academic institutions and ... participating national laboratories include Argonne, Brookhaven, Lawrence Berkeley, ...
(Date:8/20/2014)... 20, 2014 /PRNewswire-iReach/ -- A case study from ... the school,s bioengineering department and the Intel® Internet ... Software Academic Program, UCSD,s research focuses on exploring ... body.  Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... work of Dr. Todd P. Coleman , ...
(Date:8/19/2014)... Shimadzu Scientific Instruments has introduced ... Nexera-i, adding to the company’s extensive line-up of ... intuitive operating environment, and full automation, the i-Series ... for conventional to ultra-high-speed analysis. , ... design so users can begin building the lab ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
... 19, 2011 Tissue Genesis, Inc., an emerging leader ... that it has begun clinical trials for peripheral vascular ... vascular grafts at the University of Louisville Hospital.  Tissue ... using the patient,s own adipose-derived adult stem cells (ASCs) ...
... Ohio New research suggests that currently available types of ... skin in laboratory tests, and may be on their way ... Researchers compared the response of synthetic skins to rat skin ... treatment, and the results indicated they both reacted similarly. ...
... 2011 Accelovance, a privately held clinical research ... Organization (CRO)" for a third consecutive year. The ... Gaylord National Hotel and Convention Center, Washington, D.C., ... to honor and generate recognition of the efforts, ...
Cached Biology Technology:Tissue Genesis Begins FDA-Approved Clinical Trial 2Tissue Genesis Begins FDA-Approved Clinical Trial 3For testing skin cream, synthetic skin may be as good as the real thing 2For testing skin cream, synthetic skin may be as good as the real thing 3Continued Recognition for Excellence; Accelovance Named 2011 "Best CRO" 2
(Date:8/21/2014)... SHELTON, Conn. , Aug. 21, 2014 ... on the growing mobile commerce market, announced today that ... purchase common stock to be issued in its proposed ... been approved for listing on The Nasdaq Capital Market, ... of the common stock and warrants, and will trade ...
(Date:8/21/2014)... aimed at improving the food intake, health and quality ... is among three projects at the University of Waterloo ... Canadian Institutes of Health Research (CIHR). , Professor ... at Waterloo, and a Schlegel research chair in nutrition ... investigate why many Canadians living in long-term care homes ...
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2
... available in German . ... have jaws have four fins or limbs, one pair in front ... of evolution, into a marvelous variety of fins, legs, arms, flippers, and ... arrangement of two pairs of appendages? Because we have a belly. ...
... Yale School of Medicine researchers provides insight into how much ... reproductive health. Published in the Jan. 27 issue of ... of reproductive-age women had never discussed their reproductive health with ... provider less than once a year or never. ...
... embryonic stem cells of high clinical quality. It also allows ... The discovery is a big step forward for stem cell ... and thereby curing serious illnesses such as diabetes and Parkinson,s ... from surplus in vitro fertilized (IVF) embryos that are not ...
Cached Biology News:How did we get 4 limbs? Because we have a belly 2How did we get 4 limbs? Because we have a belly 3The science of baby-making still a mystery for many women 2New method increases supply of embryonic stem cells 2
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
Biology Products: